Share on LinkedInShare on LinkedIn

ARTICLE · 05 DECEMBER 2019

CAFC Reverses PTAB's Obviousness Ruling In OSI v. Apotex

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In OSI Pharmaceuticals, LLC v. Apotex Inc., No. 2018-1925 (Fed. Cir. Oct. 4, 2019), the CAFC reversed the PTAB's conclusion that a reasonable factfinder could conclude a person of ordinary skill...

United StatesIntellectual Property

In OSI Pharmaceuticals, LLC v. Apotex Inc., No. 2018-1925 (Fed. Cir. Oct. 4, 2019), the CAFC reversed the PTAB's conclusion that a reasonable factfinder could conclude a person of ordinary skill in the art would have had a reasonable expectation of success in using erlotinib to treat non-small cell lung cancer in a mammal.  The CAFC held "the Board misinterpreted the asserted references to teach more than substantial evidence supports," and the references provided no more than hope, which is "not enough to create a reasonable expectation of success in a highly unpredictable art."  This case involved a patent covering the use of erlotinib to treat non-small cell lung cancer.  Further discussion of the decision can be found on Finnegan's Federal Circuit IP Blog.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from